Fulcrum Therapeutics Inc [FULC] stock prices are up 4.24% to $6.88 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FULC shares have gain 28.12% over the last week, with a monthly amount glided 124.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fulcrum Therapeutics Inc [NASDAQ: FULC] stock has seen the most recent analyst activity on May 15, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $10 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on September 13, 2024, and dropped its price target to $4. On September 12, 2024, downgrade downgraded it’s rating to Hold. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $4 on September 12, 2024. Leerink Partners downgraded its rating to a Market Perform but $4 remained the price target by the analyst firm on September 12, 2024. Cantor Fitzgerald downgraded its rating to Neutral for this stock on September 12, 2024. In a note dated September 12, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $10 to $2.
The stock price of Fulcrum Therapeutics Inc [FULC] has been fluctuating between $2.32 and $10.13 over the past year. Currently, Wall Street analysts expect the stock to reach $9.86 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $6.88 at the most recent close of the market. An investor can expect a potential return of 43.31% based on the average FULC price forecast.
Analyzing the FULC fundamentals
Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.16%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.44 points at the first support level, and at 6.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.19, and for the 2nd resistance point, it is at 7.50.
Ratios To Look Out For
It’s worth pointing out that Fulcrum Therapeutics Inc [NASDAQ:FULC]’s Current Ratio is 28.71. As well, the Quick Ratio is 28.71, while the Cash Ratio is 5.21. Considering the valuation of this stock, the price to sales ratio is 4.64, the price to book ratio is 1.63.
Transactions by insiders
Recent insider trading involved Tourangeau Greg, Principal Accounting Officer, that happened on May 08 ’25 when 498.0 shares were sold.
